Pfizer has been developing an HIV therapy and a treatment for asthma and lung disease in collaboration with Germany's Altana AG. According to an Associated Press report, Pfizer had to scrap its development program midway when experiments didn't show any favorable results for the patients.
The drug manufacturer says the drug is not goon enough to enhance the effectiveness of standard triple-drug HIV therapies in patients who couldn't respond to available antiretroviral therapies.
Pfizer has also declared it will give the rights to the compound back to its developer, Shionogi & Co. of Japan. Thus, the leading drug manufacturer has now only one HIV drug called maraviroc phenomenal in preventing HIV from entering cells.
As far as the treatment for asthma and lung disease is concerned, Pfizer spokesman Stephen Lederer makes it clear the company currently has no treatment in its pipeline. He says, "Pfizer does have a huge and growing pipeline. When we last gave an update we talked about 222 development programs...and it's grown by 20 percent in two to three years."
